Stevanato Group Investor Presentation
High-Value Solutions Address Unique Storage & Packaging
Requirements for Biologics
Pharmaceutical innovation is driving advancements in more
complex biologics, often administered by injection
Biologics are challenging to stabilize and administer due to
complexity, sensitivity, and viscosity
Stevanato is present in three of the four potential blockbusters¹
approved in 2022 by FDA, all of which were biologics
Ideally suited HVS with
superior mechanical
and physiochemical
characteristics
EZ-fill NexaⓇ
EZ-fill AlbaⓇ
Share of BDS Revenue from Biologics, Excluding
Covid-19
(% of BDS Revenue excl. Covid-19)
16%
FY 2021
28%
19%
FY 2022
FY 2023
Share of BDS revenue from biologics including revenue related to Covid-19 can be
found in the Company's Annual Report on Form 20-F filed with the SEC for the
fiscal years ended December 31, 2023, 2022 and 2021.
-
Strong secular tailwinds in biologics - including rising interest for GLP-1s – are increasing demand for HVS.
We expect that continued advancements in biologics will drive durable, organic growth
1Source: IQVIA
SG, Stevanato Group
Stevanato Group Investor Presentation, March 2024
16View entire presentation